ClinVar Miner

Submissions for variant NM_000256.3(MYBPC3):c.1484G>A (p.Arg495Gln)

gnomAD frequency: 0.00004  dbSNP: rs200411226
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 33
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Biesecker Lab/Clinical Genomics Section, National Institutes of Health RCV000171824 SCV000054769 pathogenic Primary familial hypertrophic cardiomyopathy 2013-06-24 criteria provided, single submitter research
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000168090 SCV000198912 pathogenic Hypertrophic cardiomyopathy 2022-03-23 criteria provided, single submitter clinical testing The p.Arg495Gln variant in MYBPC3 has been reported in >20 individuals with HCM and segregated with disease in 5 affected relatives from 3 families (Niimura 1998 PMID: 9562578, Maron 2001 PMID: 11499718, Van Driest 2004 PMID: 15519027, Ehlermann 2008 PMID: 18957093, Fokstuen 2008 PMID: 18409188, Morita 2008 PMID: 18403758, Millat 2010 PMID: 20624503, Fokstuen 2011 PMID: 21239446, Brito 2012 PMID: 22857948, Lopes 2013 PMID: 23396983, Marsiglia 2013 PMID: 24093860, Kapplinger 2014 PMID: 24510615, Walsh 2017 PMID: 27532257, LMM data). However, multiple unaffected relatives from different families also carried this variant, at least 6 of whom were over the age of 50 (Brito 2012 PMID: 22857948, LMM data), suggesting reduced penetrance. This variant has also been reported by other clinical laboratories in ClinVar (Variation ID 164113) and has been identified in 0.005% (1/17974) of East Asian chromosomes and 0.004% (5/112974) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org). Please note that for diseases with clinical variability or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. In vitro functional studies suggest that carriers of this variant exhibit heightened expression of MYBPC3 as compared to controls, leading to an abundance of the mutant protein in cardiac tissue (Helms 2014 PMID: 25031304). However, it is unclear how this would impact cardiac function. Computation tools and conservation analysis are consistent with pathogenicity. In addition, 2 different amino acid changes at this position (p.Arg495Gly and p.Arg495Trp) have been reported in multiple individuals with HCM (Niimura 1998 PMID: 9562578, Maron 2001 PMID: 11499718, García-Castro 2009 PMID: 19150014, Martín 2009 PMID: 18713777, Rodríguez-García 2010 PMID: 20433692, Brito 2012 PMID: 22857948, Coto 2012 PMID: 22765922, Lopes 2013 PMID: 23396983), suggesting that changes at this position are not tolerated. In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant HCM; however, it should be noted that penetrance may be reduced. ACMG/AMP Criteria applied: PS4, PM2_Supporting, PP1_Moderate, PP3, PM5_supporting.
GeneDx RCV000223693 SCV000208030 pathogenic not provided 2023-10-17 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant does not alter protein structure/function; The p.(R495Q) mutant peptide was predominantly expressed compared to wild-type protein in heart tissue specimens from two HCM patients, though the precise correlation to phenotype is yet to be determined (PMID: 25031304); This variant is associated with the following publications: (PMID: 34598319, 31308319, 31006259, 34542152, 15519027, 11499718, 15115610, 16715312, 18403758, 18409188, 18957093, 20031618, 20019025, 20624503, 21415409, 22857948, 23396983, 23861362, 24093860, 21310275, 24510615, 18761664, 18803133, 9562578, 26671970, 27532257, 28166811, 28024942, 28797094, 29447731, 29121657, 29907873, 30871747, 31737537, 30847666, 31447099, 32480058, 33500567, 34540771, 33673806, 27737317, 32746448, 33407484, 33087929, 34400558, 35626289, 35653365, 35535697, 25031304)
Invitae RCV000168090 SCV000218744 pathogenic Hypertrophic cardiomyopathy 2024-01-30 criteria provided, single submitter clinical testing This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 495 of the MYBPC3 protein (p.Arg495Gln). This variant is present in population databases (rs200411226, gnomAD 0.006%). This missense change has been observed in individuals with hypertrophic cardiomyopathy (PMID: 11499718, 20019025, 22857948, 23396983, 24093860). ClinVar contains an entry for this variant (Variation ID: 164113). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. This variant disrupts the p.Arg495 amino acid residue in MYBPC3. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 18403758, 19659763, 20624503). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Laboratory of Genetics and Molecular Cardiology, University of São Paulo RCV000201509 SCV000256159 likely pathogenic Hypertrophic cardiomyopathy 4 criteria provided, single submitter clinical testing
Blueprint Genetics RCV000171824 SCV000264026 pathogenic Primary familial hypertrophic cardiomyopathy 2015-03-18 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV004551314 SCV000372358 pathogenic MYBPC3-related disorder 2016-06-14 criteria provided, single submitter clinical testing Across a selection of the available literature, the c.1484G>A (p.Arg495Gln) variant has been reported in a heterozygous state in 18 patients with hypertrophic cardiomyopathy, one patient with left ventricular noncompaction cardiomyopathy, two individuals with an indeterminate status, and in a compound heterozygous state in one individual with hypertrophic cardiomyopathy (Niimura et al. 1998; Zeller et al. 2006; Ehlermann et al. 2008; Millat et al. 2010; Antonio et al. 2011; Marsiglia et al. 2013; Helms et al. 2014). The p.Arg495Gln was also found in a heterozygous state in one unaffected individual but was absent from 536 control chromosomes. The variant is reported at a frequency of 0.00001 in the European (Finnish) population of the Exome Aggregation Consortium but this is based on one allele so is presumed to be rare. Helms et al. (2014) demonstrated that heart tissue samples carrying the p.Arg495Gln variant exhibited higher MYBPC3 expression and transcript levels but no increase in protein abundance when compared to control heart tissues. MYBPC3 variants have displayed reduced penetrance and variable expressivity. Based on the collective evidence, the p.Arg495Gln variant is classified as pathogenic for MYBPC3-related disorders.
Centre for Mendelian Genomics, University Medical Centre Ljubljana RCV000168090 SCV000492795 likely pathogenic Hypertrophic cardiomyopathy 2015-09-07 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000171824 SCV000696312 pathogenic Primary familial hypertrophic cardiomyopathy 2021-08-09 criteria provided, single submitter clinical testing Variant summary: The variant, MYBPC3 c.1484G>A (p.Arg495Gln) results in a conservative amino acid change located in the Immunoglobulin-like domain (Immunoglobulin subtype 2) and Immunoglobulin I-set domain of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 2.4e-05 in 253236 control chromosomes (gnomAD and publications) and has been reported in the literature in multiple individuals affected with Hypertrophic Cardiomyopathy (example, Helms_2014, Marsiglia_2013, Ng_2013, Lopes_2013, Millat_2010, Morita_2008, VanDriest_2004, Niimura_1998, Viswanathan_2017). In one family, this variant cosegregates with HCM in three affected family members, however, one unaffected family member whose age was above the age of onset carried this variant implying reduced penetrance or later onset (Niimura_1998). Two co-occurrences with other likely pathogenic variants (MYBPC3 p.Tyr1172fs, TNNI3 Arg141Gln) have been reported in two HCM patients, respectively (Millat_2010, Morita_2008). These data indicate that the variant is very likely to be associated with disease. Experimental evidence evaluating the impact of the variant on protein function, does not allow convincing conclusions about the variant effect (Helms_2014). However, myocardial tissue obtained from a human HCM subject that harbors the variant show molecular signatures of aberrant calcium signaling (increased Ca2+/Calmodulin dependent protein kinase II (CaMKII) activation and reduced SERCA2 (Sarcoplasmic/endoplasmic reticulum calcuium ATPase 2) mRNA levels, (Helms_2016). Experimental evidence suggest that mutations causative of HCM in both thick and thin sarcomere filaments may lead to abnormal calcium handling and increase the risk of arrhythmia in HCM (Helms_2016). Multiple ClinVar submissions from clinical diagnostic laboratories (evaluation after 2014) cites the variant as likely pathogenic/pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Ambry Genetics RCV000589860 SCV000739944 pathogenic Cardiovascular phenotype 2021-09-09 criteria provided, single submitter clinical testing The p.R495Q pathogenic mutation (also known as c.1484G>A), located in coding exon 17 of the MYBPC3 gene, results from a G to A substitution at nucleotide position 1484. The arginine at codon 495 is replaced by glutamine, an amino acid with highly similar properties. This alteration has been reported in multiple unrelated individuals with hypertrophic cardiomyopathy (HCM) and has been reported to segregate with disease in families (Niimura H et al. N Engl J Med. 1998;338(18):1248-57; Maron BJ et al. Am J Cardiol. 2011;107(4):604-8; Brito D et al. Rev Port Cardiol. 2012;31(9):577-87; Kapplinger JD et al. J Cardiovasc Transl Res. 2014;7(3):347-61; Mattos BP et al. Arq. Bras. Cardiol., 2016 Sep;107:257-265). This variant has also been detected in noncompaction and dilated cardiomyopathy cohorts (van Waning JI et al. J Am Coll Cardiol. 2018 02;71(7):711-722; Sousa A et al. Rev Port Cardiol (Engl Ed). 2019 Feb;38(2):129-139). In addition, alterations affecting the same amino acid (p.R495W (c.1483C>T) and p.R495G (c.1483C>G)) have also been reported in association with HCM (Page SP et al. Circ Cardiovasc Genet. 2012;5(2):156-66; García-Castro M et al. Rev Esp Cardiol. 2009;62(1):48-56). Based on the supporting evidence, p.R495Q is interpreted as a disease-causing mutation.
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center RCV000201509 SCV000744850 pathogenic Hypertrophic cardiomyopathy 4 2015-09-21 criteria provided, single submitter clinical testing
Eurofins Ntd Llc (ga) RCV000223693 SCV000855753 likely pathogenic not provided 2017-08-01 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV000763243 SCV000893879 pathogenic Hypertrophic cardiomyopathy 4; Left ventricular noncompaction 10 2018-10-31 criteria provided, single submitter clinical testing
Institute of Human Genetics Munich, Klinikum Rechts Der Isar, TU München RCV000201509 SCV001150174 pathogenic Hypertrophic cardiomyopathy 4 2018-05-23 criteria provided, single submitter clinical testing
Agnes Ginges Centre for Molecular Cardiology, Centenary Institute RCV000168090 SCV001156327 pathogenic Hypertrophic cardiomyopathy 2018-05-02 criteria provided, single submitter research The MYBPC3 Arg495Gln variant has been described in many HCM probands and has been reported to segregate with disease in several families (see literature). A study analysing the transcript and protein levels in two septal myectomy patients carrying the MYBPC3 Arg495Gln variant revealed that not only did the patients exhibit a 2-fold increase in MYBPC3 protein expression but were also found to predominately express the mutant peptide (Helms AS, et al., 2014), which is supportive of the pathogenic role of the variant. The variant is present at a low frequency in the Genome Aggregation Database (http://gnomad.broadinstitute.org/). We identified this variant in 2 HCM probands. One proband was diagnosed after they suffered resuscitated cardiac arrest in childhood, family screening identified an additional 3 affected family members in which the variant segregated (Ross SB, et al., 2017). The second proband does not have a family history of disease (Ingles et al., 2017). Interestingly, different rare variants at this position (Arg495Trp, Arg495Gly) have also been reported in HCM cases, suggesting that an amino acid substitution at this site may not be tolerated. Computational tools SIFT, PolyPhen2, and MutationTaster predict this variant to have a deleterious effect. Based on the adapted ACMG guidelines (Kelly MA, et al., 2018) this variant has been reported in more than 15 HCM probands (PS4), segregates with disease in multiple families (PP1_strong), is rare in the general population (PM2) and in silico tools predict it to be deleterious (PP3), therefore we classify MYBPC3 Arg495Gln as "pathogenic".
CeGaT Center for Human Genetics Tuebingen RCV000223693 SCV001249486 pathogenic not provided 2023-07-01 criteria provided, single submitter clinical testing MYBPC3: PS4, PM2, PM5, PP1:Moderate, PP3
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario RCV001171139 SCV001333823 pathogenic Cardiomyopathy 2021-07-08 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV001171139 SCV001360091 pathogenic Cardiomyopathy 2023-05-16 criteria provided, single submitter clinical testing This missense variant replaces arginine with glutamine at codon 495 in the Ig-like domain C3 of the MYBPC3 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). An experimental functional study using a transgenic pig model heterozygous for this variant has shown a phenotype of myocardial fibrosis as well as reduced MYBPC3 expression levels in cardiac fibroblasts (PMID: 36357371). This variant has been reported in over 20 unrelated individuals affected with hypertrophic cardiomyopathy (PMID: 11499718, 20019025, 22857948, 23396983, 24093860, 28024942, 28615295, 29121657, 29907873, 32746448, 35626289). This variant has been shown to segregate with hypertrophic cardiomyopathy in three different families (PMID: 9562578, 27737317, 29121657). This variant has been identified in 6/249188 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Different variants occurring at the same codon, p.Arg495Gly and p.Arg495Trp, are well documented pathogenic mutations (Clinvar variation ID: 42537 and 164114), indicating that arginine at this position is important for MYBPC3 protein function. Based on the available evidence, this variant is classified as Pathogenic.
Institute of Human Genetics, University of Leipzig Medical Center RCV000201509 SCV001428773 pathogenic Hypertrophic cardiomyopathy 4 2019-10-07 criteria provided, single submitter clinical testing
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen RCV000223693 SCV001447092 pathogenic not provided 2020-10-23 criteria provided, single submitter clinical testing
Revvity Omics, Revvity RCV000223693 SCV002017657 pathogenic not provided 2021-06-05 criteria provided, single submitter clinical testing
Laan Lab, Human Genetics Research Group, University of Tartu RCV000201509 SCV002538611 likely pathogenic Hypertrophic cardiomyopathy 4 2021-05-01 criteria provided, single submitter research
Institute of Human Genetics, University Hospital Muenster RCV002287371 SCV002577925 pathogenic See cases 2021-12-21 criteria provided, single submitter clinical testing ACMG categories: PS5,PM1,PM2,PM5,PP3,PP5
MGZ Medical Genetics Center RCV000201509 SCV002579905 pathogenic Hypertrophic cardiomyopathy 4 2022-05-11 criteria provided, single submitter clinical testing
Baylor Genetics RCV000201509 SCV003835506 pathogenic Hypertrophic cardiomyopathy 4 2022-10-13 criteria provided, single submitter clinical testing
Baylor Genetics RCV003147345 SCV003835517 pathogenic Left ventricular noncompaction 10 2022-10-13 criteria provided, single submitter clinical testing
Institute of Human Genetics Munich, Klinikum Rechts Der Isar, TU München RCV003147345 SCV004045792 pathogenic Left ventricular noncompaction 10 2022-10-31 criteria provided, single submitter clinical testing
Center of Genomic medicine, Geneva, University Hospital of Geneva RCV000201509 SCV004100671 pathogenic Hypertrophic cardiomyopathy 4 2023-03-10 criteria provided, single submitter clinical testing
All of Us Research Program, National Institutes of Health RCV000168090 SCV004834616 pathogenic Hypertrophic cardiomyopathy 2024-01-06 criteria provided, single submitter clinical testing This missense variant replaces arginine with glutamine at codon 495 in the Ig-like domain C3 of the MYBPC3 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). An experimental functional study using a transgenic pig model heterozygous for this variant has shown a phenotype of myocardial fibrosis as well as reduced MYBPC3 expression levels in cardiac fibroblasts (PMID: 36357371). This variant has been reported in over 20 unrelated individuals affected with hypertrophic cardiomyopathy (PMID: 11499718, 20019025, 22857948, 23396983, 24093860, 28024942, 28615295, 29121657, 29907873, 32746448, 35626289). This variant has been shown to segregate with hypertrophic cardiomyopathy in three different families (PMID: 9562578, 27737317, 29121657). This variant has been identified in 6/249188 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Different variants occurring at the same codon, p.Arg495Gly and p.Arg495Trp, are well documented pathogenic mutations (Clinvar variation ID: 42537 and 164114), indicating that arginine at this position is important for MYBPC3 protein function. Based on the available evidence, this variant is classified as Pathogenic.
Stanford Center for Inherited Cardiovascular Disease, Stanford University RCV000223693 SCV000280212 likely pathogenic not provided 2015-03-17 no assertion criteria provided clinical testing Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. MYBPC3 p.Arg495Gln We first reviewed the variant in October 2013. We re-reviewed it October 15th, 2015 and found even stronger data in favor of pathogenicity. The variant has been seen in at least 25 unrelated cases of HCM (not including this patient) with some segregation data in one family. ~10 of these cases may be attributable to a Brazilian founder. Niimura et al. (1998, Seidman group) reported this variant in an individual with HCM within a cohort of 16 families. Three affected family members all had the variant as did two individuals with indeterminate phenotype (described by the authors as left ventricular hypertrophy with confounding factors such as hypertension). Same family is also included in a later paper by the same group (Maron B et al. 2001). Van Driest et al (2004) identified this variant in one patient in a cohort of 389 unrelated patients with HCM at Mayo clinic. No information is given on the patient's phenotype. They report no segregation data. Ehlermann (2008) observed this variant in one HCM patient from a cohort of 87 patients with HCM. Mutation carriers exhibited no additional mutations in genes MYH7, TNNT2, TNNI3, ACTC and TPM1. There is no specific reported clinical data on the patient with this variant. Morita et al. (2008) reported this variant in an individual with HCM while looking at a cohort of 84 children with idiopathic cardiac hypertrophy diagnosed before age 15. This individual also carried TNNI3 Arg141Gln (which we classify as likely disease causing) in addition to the MYBPC3 Arg495Gln variant. No segregation data or parental data was included. Individual phenotypic details were not provided (though onset was pediatric in all cases). Frisso et al (2009) report a patient with HCM from their Italian cohort who underwent analysis of 8 sarcomere genes. He was diagnosed at 2 years of age and his father had left ventricular non-compaction and also carried the variant. Kaski et al (2009, McKenna's group) observed this variant in one patient in a cohort of 79 patients diagnosed with HCM at age 13 years or younger from London. They did not give specific data regarding the patient with this variant nor segregation data. This could overlap with a later report from the same group (Captur et al 2014). Marsiglia et al (2013) observed the variant in 10 of 268 unrelated HCM patients from their Brazilian cohort who underwent sequencing of MYH7, MYBPC3, TNNT2. Ackerman's group observed the variant in 7 patients in their cohort of 1053 unrelated patients with HCM who underwent DHLPC-based analysis of 9 sarcomere genes at Mayo (Bos et al 2014). Note that these cases may overlap with prior reports by Ackerman's group (ex. van Driest et al 2004) and perhaps also with internal data from genetic testing labs. Sharlene Day's group included two unrelated HCM patients with this variant in a recent paper on transcription levels in MYBPC3 carriers (Helms et al 2014). That case may overlap with internal data from clinical labs. We have seen the variant in one other patient with HCM in our center. In silico analysis with PolyPhen-2 predicts the variant to be probably damaging. Mutation Taster predicts this variant to be disease-causing. The arginine at codon 495 is conserved across species, as are neighboring amino acids. Other variants have been reported in association with disease at this codon (Arg495Trp, Arg495Gly) and nearby codons (Thr494lle; Gly490Arg). Niimura notes that this variant is in the 244-amino acid segment that spans the phosphorylation domain of the molecule. Helms et al (2014) observed an increase in expression of the mutant peptide in heart tissue of two unrelated HCM patients with this variant. In total the variant has not been seen in ~8,000 laboratory controls, published controls and individuals from publicly available population datasets. There is no variation at codon 495 listed in the NHLBI Exome Sequencing Project dataset, which currently includes variant calls on ~6,500 Caucasian and African American individuals (as of 10/15/13). There is also no variation at this codon listed in dbSNP or 1000 genomes (as of 10/15/13). The variant was not observed in the following laboratory and published control samples: Familion internal control population of over 400 unrelated, ethnically diverse, presumed healthy individuals. Kaski et al did not observe this variant in 200 presumed healthy controls. Morita reports this variant was absent in 180 unrelated persons matched by ancestral origin to the subjects and in more than 1000 chromosomes of unaffected persons. Van Driest reported this variant was not present in 400 reference alleles (200 from ethnically matched Caucasian Americans, and 200 from ethnically diverse African Americans; same as Bos et al 2014).
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen RCV000223693 SCV001742965 pathogenic not provided no assertion criteria provided clinical testing
Clinical Genetics, Academic Medical Center RCV000223693 SCV001921289 pathogenic not provided no assertion criteria provided clinical testing
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ RCV000223693 SCV001951130 pathogenic not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.